Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Eichhorst, B ^a   Hallek, M ^a   Dreyling, M ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIBODY; ANTILEUKEMIC AGENT; BENDAMUSTINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; OFATUMUMAB; PURINE DERIVATIVE; RITUXIMAB; STEROID;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DIAGNOSTIC TEST; DRUG DOSE REDUCTION; DRUG MEGADOSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LABORATORY TEST; LYMPH NODE BIOPSY; LYMPHOCYTE COUNT; LYMPHOCYTOMA; MALIGNANT TRANSFORMATION; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER; SURVIVAL TIME; TREATMENT RESPONSE;

ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD5; DRUG THERAPY; EUROPE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, IGE; RECURRENCE; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77954340617     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq180     Document Type: Article

References (12)

1. Ries La EMP, Kosary CL, Hankey BF et al. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute 2005 based on November 2004 SEER data submission. Report No.: http://seer.cancer.gov/csr/1975_2002/.
2. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
3. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
4. Dö hner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
5. Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506-1514.
6. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
7. Hallek M, Fingerle-Rowson G, Fink A et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009; 114: Abstr 535.
8. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
9. Robak T, Moiseev S, Dmoszynska A et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the International Randomized phase III REACH trial. Blood 2008; 112: Abstr LBA-1.
10. Knauf W, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384.
11. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
12. Dreger P, Corradini P, Kimby E et al. on behalf of the Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12-17.